Monte Rosa Therapeutics Initiates Phase 2 Clinical Study, Triggers Novartis Milestone Payment

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) announced the achievement of a milestone with the initiation of a Phase 2 clinical study for its VAV1-directed molecular glue degrader, MRT-6160 (DDY391), in patients with Sjögren's disease. This milestone triggers a potential payment under its global exclusive development and commercialization license agreement with Novartis, which could amount to up to $2.1 billion in development, regulatory, and sales milestones. The company filed an 8-K regarding this event.